Ponatinib-Induced Cerebrovascular Accident (CVA)

Ponatinib is a highly potent tyrosine kinase inhibitor shown to have excellent outcomes in the treatment of acute and chronic leukemias. Despite its high efficacy, ponatinib has been shown to carry an increased risk for cardiovascular adverse events, not attributable to a known mechanism. We present...

Descripción completa

Detalles Bibliográficos
Autores principales: Azad, Farhan, Zhang, Jiahua, Miranda, Clive J, Gravina, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829188/
https://www.ncbi.nlm.nih.gov/pubmed/36632247
http://dx.doi.org/10.7759/cureus.32383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9829188/
https://www.ncbi.nlm.nih.gov/pubmed/36632247
http://dx.doi.org/10.7759/cureus.32383

Ejemplares similares